Table 1.

Antibiotic susceptibility profile of P. rettgeri MRSN 845308

Antibiotic	Method*	MIC (µg ml−1)	Interpretation†
Amikacin	Vitek 2	>=64	R
Ampicillin/Sulbactam	Vitek 2	>=32	R
Ampicillin	Vitek 2	>=32	R
Aztreonam	Vitek 2	>=64	R
Cefepime	Vitek 2	>=64	R
Cefiderocol	BMD	>32	R
Ceftazidime	Vitek 2	>=64	R
Ceftazidime/Avibactam	Vitek 2	>=16/4	R
Ceftolozane/Tazobactam	Vitek 2	>8/4	R
Ceftriaxone	Vitek 2	>=64	R
Ciprofloxacin	Vitek 2	>=4	R
Colistin	BMD	>4	R
Delafloxacin	BMD	>1	R
Eravacycline	BMD	>8	ns
Ertapenem	Vitek 2	>=8	R
Gentamicin	Vitek 2	>=16	R
Imipenem	Vitek 2	>=16	R
Imipenem/Relebactam	BMD	>16/4	R
Meropenem	Vitek 2	>=16	R
Meropenem/Vaborbactam	BMD	>16/8	R
Omadacycline	BMD	>8	R
Piperacillin/Tazobactam	Vitek 2	>=128	R
Plazomicin	BMD	>4	R
Tobramycin	Vitek 2	>=16	R
Trimethoprim/Sulfamethoxazole	Vitek 2	>=320	R

*AST testing on the Vitek2 was performed using the AST-GN95 and AST-XN09 panels. BMD, broth microdilution.

†R, resistant; S, sensitive; NS, non-susceptible. Breakpoints based on CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition (2020). No intermediate or resistant breakpoints have been established for eravacycline with Enterobacterales to date.